Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation coexisting in Chinese patients with lung adenocarcinoma.

Zhu J, Cai L, Yang H, Wen Y, Wang J, Rong T, Shao J, Zhang L.

Thorac Cancer. 2014 Sep;5(5):411-6. doi: 10.1111/1759-7714.12111. Epub 2014 Aug 25.

2.

Feasibility of computed tomography-guided core needle biopsy in producing state-of-the-art clinical management in Chinese lung cancer.

Chen HJ, Yang JJ, Fang LY, Huang MM, Yan HH, Zhang XC, Xu CR, Wu YL.

Thorac Cancer. 2014 Mar;5(2):155-61. doi: 10.1111/1759-7714.12076. Epub 2014 Mar 3.

3.

Moving molecularly directed therapies to the first-line in ALK-positive lung cancer: crizotinib is just the beginning.

Klempner SJ, Raufi A, Ou SH.

Transl Lung Cancer Res. 2015 Oct;4(5):649-52. doi: 10.3978/j.issn.2218-6751.2015.07.03.

4.

Association between EML4-ALK fusion gene and thymidylate synthase mRNA expression in non-small cell lung cancer tissues.

Xu CW, Wang G, Wang WL, Gao WB, Han CJ, Gao JS, Zhang LY, Li Y, Wang L, Zhang YP, Tian YW, Qi DD.

Exp Ther Med. 2015 Jun;9(6):2151-2154. Epub 2015 Mar 19.

5.

The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients.

Fu S, Liang Y, Lin YB, Wang F, Huang MY, Zhang ZC, Wang J, Cen WJ, Shao JY.

PLoS One. 2015 Apr 23;10(4):e0124354. doi: 10.1371/journal.pone.0124354. eCollection 2015.

6.

Detection of EML4-ALK in lung adenocarcinoma using pleural effusion with FISH, IHC, and RT-PCR methods.

Liu L, Zhan P, Zhou X, Song Y, Zhou X, Yu L, Wang J.

PLoS One. 2015 Mar 18;10(3):e0117032. doi: 10.1371/journal.pone.0117032. eCollection 2015.

7.

Novel covalent modification of human anaplastic lymphoma kinase (ALK) and potentiation of crizotinib-mediated inhibition of ALK activity by BNP7787.

Parker AR, Petluru PN, Nienaber VL, Zhao M, Ayala PY, Badger J, Chie-Leon B, Sridhar V, Logan C, Kochat H, Hausheer FH.

Onco Targets Ther. 2015 Feb 4;8:375-83. doi: 10.2147/OTT.S73690. eCollection 2015.

8.

Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer.

Kelleher FC, Solomon B, McArthur GA.

J Pers Med. 2012 Apr 10;2(2):35-49. doi: 10.3390/jpm2020035. Review.

9.

Molecular docking studies shows tivozanib and lapatinib as potential inhibitors of EML4-ALK translocation mediated fusion protein in non small cell lung cancer.

Ramshankar V, Yegnaswamy S, P K, Arvind K.

Bioinformation. 2014 Oct 30;10(10):658-63. doi: 10.6026/97320630010658. eCollection 2014.

10.

Clinical Utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer.

Faugeroux V, Pailler E, Auger N, Taylor M, Farace F.

Front Oncol. 2014 Nov 5;4:281. doi: 10.3389/fonc.2014.00281. eCollection 2014. Review.

11.
12.

Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.

Schink JC, Trosman JR, Weldon CB, Siziopikou KP, Tsongalis GJ, Rademaker AW, Patel JD, Benson AB 3rd, Perez EA, Gradishar WJ.

J Natl Cancer Inst. 2014 Sep 12;106(10). pii: dju256. doi: 10.1093/jnci/dju256. Print 2014 Oct.

13.

Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS.

Korpanty GJ, Graham DM, Vincent MD, Leighl NB.

Front Oncol. 2014 Aug 11;4:204. doi: 10.3389/fonc.2014.00204. eCollection 2014. Review.

14.

Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase Inhibitory Activities.

Liu Z, Ai J, Peng X, Song Z, Wu K, Zhang J, Yao Q, Chen Y, Ji Y, Yang Y, Geng M, Zhang A.

ACS Med Chem Lett. 2014 Feb 8;5(4):304-8. doi: 10.1021/ml400373j. eCollection 2014 Apr 10.

15.

Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group.

Kim H, Shim HS, Kim L, Kim TJ, Kwon KY, Lee GK, Chung JH; Korean Cardiopulmonary Pathology Study Group.

Korean J Pathol. 2014 Feb;48(1):1-9. doi: 10.4132/KoreanJPathol.2014.48.1.1. Epub 2014 Feb 25. Review.

16.

Crizotinib: A comprehensive review.

Sahu A, Prabhash K, Noronha V, Joshi A, Desai S.

South Asian J Cancer. 2013 Apr;2(2):91-7. doi: 10.4103/2278-330X.110506. Review.

17.

Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer.

de Figueiredo-Pontes LL, Wong DW, Tin VP, Chung LP, Yasuda H, Yamaguchi N, Nakayama S, Jänne PA, Wong MP, Kobayashi SS, Costa DB.

J Thorac Oncol. 2014 Feb;9(2):248-53. doi: 10.1097/JTO.0000000000000050.

18.

The pivotal role of pathology in the management of lung cancer.

Davidson MR, Gazdar AF, Clarke BE.

J Thorac Dis. 2013 Oct;5 Suppl 5:S463-78. doi: 10.3978/j.issn.2072-1439.2013.08.43. Review.

19.

Crizotinib in the treatment of non-small-cell lung carcinoma.

Płużański A, Piórek A, Krzakowski M.

Contemp Oncol (Pozn). 2012;16(6):480-4. doi: 10.5114/wo.2012.32477. Epub 2013 Jan 4.

20.

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M.

J Thorac Oncol. 2013 Jul;8(7):823-59. doi: 10.1097/JTO.0b013e318290868f. Erratum in: J Thorac Oncol. 2013 Oct;8(10):1343.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk